Biliary innate immunity and cholangiopathy

Area of Science:

• Immunology
• Gastroenterology
• Hepatology

Background:

• The intrahepatic biliary tree contains pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), from intestinal flora.
• Human biliary epithelial cells (BEC) possess innate immune recognition systems, including Toll-like receptors (TLRs), but typically exhibit tolerance to commensal PAMPs.
• Endotoxin tolerance is vital for maintaining biliary homeostasis and preventing inappropriate inflammation.

Purpose of the Study:

• To investigate the mechanisms of endotoxin tolerance in human BEC.
• To explore the roles of negative regulators like PPAR-gamma and IRAK-M in biliary innate immunity.
• To understand how acquired immunity, particularly T-helper 1 (Th1) cytokines, influences BEC susceptibility to PAMPs and its implications in diseases like primary biliary cirrhosis (PBC).

Main Methods:

• In vivo and in vitro studies examining the expression of TLRs, PPAR-gamma, and IRAK-M in human biliary epithelium.
• Analysis of cytokine and chemokine secretion by BEC in response to PAMPs.
• Investigation of the effects of interferon-gamma (IFN-γ) on BEC signaling pathways and PAMPs susceptibility.

Main Results:

• PPAR-gamma and IRAK-M are key negative regulators of TLR signaling, contributing to endotoxin tolerance in BEC.
• PPAR-gamma expression is reduced in damaged bile ducts in PBC, correlating with impaired tolerance.
• IFN-γ, a Th1 cytokine, downregulates PPAR-gamma and upregulates TLRs in BEC, increasing susceptibility to PAMPs.
• The Th1-dominant cytokine milieu in PBC may contribute to cholangiopathy development via heightened BEC responsiveness to PAMPs.

Conclusions:

• Biliary innate immunity involves a delicate balance between PAMP recognition and tolerance, mediated by molecules like PPAR-gamma and IRAK-M.
• Dysregulation of this balance, particularly in Th1-dominant conditions like PBC, can lead to increased biliary inflammation and disease pathogenesis.
• Understanding biliary innate immunity is crucial for developing therapeutic strategies for biliary diseases.